EHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Encompass Health Corp (EHC) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and favorable options data outweigh the current technical weakness and lack of recent news catalysts. Despite the bearish short-term technical indicators, the long-term growth potential and analyst price target increase make it a solid investment opportunity.
The technical indicators for EHC are currently bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 36.367, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 96.338), with resistance levels at R1: 102.37 and R2: 104.233.
Strong financial performance in Q4 2025, with revenue up 9.94% YoY, net income up 21.32% YoY, and EPS up 21.19% YoY.
Barclays raised the price target to $153 from $150 and maintained an Overweight rating.
Favorable options sentiment with a low Put-Call Ratio (0.4 for open interest and 0.02 for volume).
Bearish technical indicators suggest short-term weakness.
Lack of recent news or event-driven catalysts.
No significant hedge fund or insider trading activity in the last quarter.
In Q4 2025, Encompass Health Corp reported a 9.94% YoY increase in revenue to $1.5446 billion. Net income rose by 21.32% YoY to $145.7 million, while EPS increased by 21.19% to 1.43. Gross margin improved slightly to 90.23%, up 0.24% YoY.
Barclays recently raised the price target for EHC to $153 from $150, maintaining an Overweight rating. This reflects positive sentiment and confidence in the company's growth prospects.
